Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: A randomized double-blind placebo-controlled trial

Phytotherapy Research

Volumn 28, Issue 10, 2014, Pages 1461-1467

  Panahi, Yunes ^a   Saadat, Alireza ^a   Beiraghdar, Fatemeh ^a   Sahebkar, Amirhossein ^b,c  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

cancer; curcumin; cytokine; inflammation; quality of life; randomized controlled trial

Indexed keywords

C REACTIVE PROTEIN; CALCITONIN GENE RELATED PEPTIDE; CURCUMIN; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; SUBSTANCE P; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CCL2 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; IL8 PROTEIN, HUMAN;

ADULT; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SARCOMA; SOLID TUMOR; STOMACH CANCER; TESTIS CANCER; UNIVERSITY OF WASHINGTON QUALITY OF LIFE INDEX; ADJUVANT CHEMOTHERAPY; AGED; BIOAVAILABILITY; CHEMISTRY; CURCUMA; IRAN; METABOLISM; MIDDLE AGED; NEOPLASMS;

ADULT; AGED; BIOLOGICAL AVAILABILITY; C-REACTIVE PROTEIN; CALCITONIN GENE-RELATED PEPTIDE; CHEMOKINE CCL2; CHEMOTHERAPY, ADJUVANT; CURCUMA; CURCUMIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; IRAN; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908503753     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5149     Document Type: Article

References (54)

1. Aggarwal BB, Gupta SC, Sung B,. 2013. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol 169: 1672 - 1692.
2. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB,. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807 - 818.
3. Barry J, Fritz M, Brender JR, et al. 2009. Determining the effects of lipophilic drugs on membrane structure by solid-state NMR spectroscopy: the case of the antioxidant curcumin. J Am Chem Soc 131: 4490 - 4498.
4. Basnet P, Skalko-Basnet N,. 2011. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 16: 4567 - 4598.
5. Bayet-Robert M, Kwiatkowski F, Leheurteur M, et al. 2010. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8 - 14.
6. Belcaro G, Hosoi M, Pellegrini L, et al. 2013. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytother Res. DOI: 10.1002/ptr.5014.
7. Bhardwaj RK, Glaeser H, Becquemont L, et al. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302: 645 - 650.
8. Burgos-Moron E, Calderon-Montano JM, Salvador J, Robles A, Lopez-Lazaro M,. 2010. The dark side of curcumin. Int J Cancer 126: 1771 - 1775.
9. Carroll RE, Benya RV, Turgeon DK, et al. 2011. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354 - 364.
10. Chainani-Wu N,. 2003. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9: 161 - 168.
11. Chainani-Wu N, Silverman S, Jr., Reingold A, et al. 2007. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 14: 437 - 446.
12. Cheng AL, Hsu CH, Lin JK, et al. 2001. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895 - 2900.
13. Cruz-Correa M, Shoskes DA, Sanchez P, et al. 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4: 1035 - 1038.
14. Cuomo J, Appendino G, Dern AS, et al. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74: 664 - 669.
15. Dhillon N, Aggarwal BB, Newman RA, et al. 2008. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491 - 4499.
16. Durgaprasad S, Pai CG, Vasanthkumar, Alvres JF, Namitha S,. 2005. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122: 315 - 318.
17. Eiro N, Vizoso FJ,. 2012. Inflammation and cancer. World J Gastrointest Surg 4: 62 - 72.
18. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G,. 2010. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62: 1137 - 1141.
19. Garcea G, Berry DP, Jones DJ, et al. 2005. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120 - 125.
20. Germano G, Allavena P, Mantovani A,. 2008. Cytokines as a key component of cancer-related inflammation. Cytokine 43: 374 - 379.
21. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R,. 2009. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 15: 5917 - 5922.
22. Gupta SC, Patchva S, Aggarwal BB,. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15: 195 - 218.
23. Hu R, Saw CL, Yu R, Kong AN,. 2010. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal 13: 1679 - 1698.
24. Hussain SP, Harris CC,. 2007. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121: 2373 - 2380.
25. Ide H, Tokiwa S, Sakamaki K, et al. 2010. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70: 1127 - 1133.
26. Jobin C, Bradham CA, Russo MP, et al. 1999. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474 - 3483.
27. Kanai M, Yoshimura K, Asada M, et al. 2011. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157 - 164.
28. Karin M,. 2006. Nuclear factor-kappaB in cancer development and progression. Nature 441: 431 - 436.
29. Kim SG, Veena MS, Basak SK, et al. 2011. Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 17: 5953 - 5961.
30. Klampfer L,. 2011. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 11: 451 - 464.
31. Mancuso C, Barone E,. 2009. Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci 30: 333 - 334.
32. Marczylo TH, Verschoyle RD, Cooke DN, et al. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60: 171 - 177.
33. McMillan DC, Elahi MM, Sattar N, et al. 2001. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41: 64 - 69.
34. Millsopp L, Frackleton S, Lowe D, Rogers SN,. 2006. A feasibility study of computer-assisted health-related quality of life data collection in patients with oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 35: 761 - 764.
35. Mohammadi A, Sahebkar A, Iranshahi M, et al. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res 27: 374 - 379.
36. Moore MM, Chua W, Charles KA, Clarke SJ,. 2010. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther 87: 504 - 508.
37. Naugler WE, Karin M,. 2008. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19 - 26.
38. Panahi Y, Sahebkar A, Amiri M, et al. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108: 1272 - 1279.
39. Panahi Y, Sahebkar A, Parvin S, Saadat A,. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49: 580 - 588.
40. Rai B, Kaur J, Jacobs R, Singh J,. 2010. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 52: 251 - 256.
41. Sahebkar A,. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94: e75 - 76; author reply e77.
42. Sahebkar A,. 2013a. Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res. DOI: 10.1002/ptr.5045
43. Sahebkar A,. 2013b. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39: 197 - 208.
44. Sahebkar A, Mohammadi A, Atabati A, et al. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res 27 (12): 1883 - 1888.
45. Semalty A, Semalty M, Rawat MS, Franceschi F,. 2010. Supramolecular phospholipids-polyphenolics interactions: the PHYTOSOME strategy to improve the bioavailability of phytochemicals. Fitoterapia 81: 306 - 314.
46. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A,. 2007. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434 - 1445.
47. Sharma RA, Euden SA, Platton SL, et al. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847 - 6854.
48. Sharma RA, McLelland HR, Hill KA, et al. 2001. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894 - 1900.
49. Shehzad A, Lee J, Lee YS,. 2013. Curcumin in various cancers. Biofactors 39: 56 - 68.
50. Shehzad A, Wahid F, Lee YS,. 2010. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489 - 499.
51. Srinivasan K,. 2007. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 47: 735 - 748.
52. Strimpakos AS, Sharma RA,. 2008. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511 - 545.
53. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N,. 2008. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 9: 243 - 250. Yamamoto Y and Gaynor RB. 2001. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142.
54. Zhou H, Beevers CS, Huang S,. 2011. The targets of curcumin. Curr Drug Targets 12: 332 - 347.